Firefly Neuroscience, Bright Minds Bioscience Collaborate to Analyze Phase 1 Data Using AI Technology

MT Newswires Live

Oct 16, 2024

Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' phase 1 study of its lead compound, BMB-101.

Financial details weren't disclosed.

The study on Bright Minds' lead compound, BMB-101, utilized electroencephalogram, or EEG headsets from Firefly's partner, Zeto, and showed positive results through qEEG data analysis with recordings taken at multiple time points.

Firefly Neuroscience said that the phase 1 trial is complete, and BMB-101 is now ready for phase 2.

Shares of Firefly were up more than 22%, while Bright Minds retreated over 35% in recent Wednesday trading.

Price: 3.84, Change: +0.71, Percent Change: +22.52

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2475919418"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2475919418\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2475919418?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-16 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475919418","market":"sg","top_or_hot":-1,"title":"Firefly Neuroscience, Bright Minds Bioscience Collaborate to Analyze Phase 1 Data Using AI Technology","media":"MT Newswires Live","content":"<html><body><p> Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' phase 1 study of its lead compound, BMB-101.</p><p>Financial details weren't disclosed.</p><p>The study on Bright Minds' lead compound, BMB-101, utilized electroencephalogram, or EEG headsets from Firefly's partner, Zeto, and showed positive results through qEEG data analysis with recordings taken at multiple time points.</p><p>Firefly Neuroscience said that the phase 1 trial is complete, and BMB-101 is now ready for phase 2.</p><p>Shares of Firefly were up more than 22%, while Bright Minds retreated over 35% in recent Wednesday trading.</p><p>Price: 3.84, Change: +0.71, Percent Change: +22.52</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Firefly Neuroscience, Bright Minds Bioscience Collaborate to Analyze Phase 1 Data Using AI Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirefly Neuroscience, Bright Minds Bioscience Collaborate to Analyze Phase 1 Data Using AI Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-16 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' phase 1 study of its lead compound, BMB-101.</p><p>Financial details weren't disclosed.</p><p>The study on Bright Minds' lead compound, BMB-101, utilized electroencephalogram, or EEG headsets from Firefly's partner, Zeto, and showed positive results through qEEG data analysis with recordings taken at multiple time points.</p><p>Firefly Neuroscience said that the phase 1 trial is complete, and BMB-101 is now ready for phase 2.</p><p>Shares of Firefly were up more than 22%, while Bright Minds retreated over 35% in recent Wednesday trading.</p><p>Price: 3.84, Change: +0.71, Percent Change: +22.52</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DRUG","symbol_name":"Bright Minds Biosciences Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2475919418","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475919418","pubTimestamp":1729089841,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' pha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DRUG":"Bright Minds Biosciences Inc","BK4134":"信息科技咨询与其它服务","AIFF":"Firefly Neuroscience, Inc.","BK4139":"生物科技"},"translate_title":"Firefly Neuroscience与Bright Minds Bioscience合作使用AI技术分析第一阶段数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRUG":0.8,"AIFF":0.9},"content_text":"Firefly Neuroscience (AIFF) said Wednesday it is collaborating with Bright Minds Biosciences (DRUG) to use Firefly's AI-driven Brain Network Analytics technology to analyze data from Bright Minds' phase 1 study of its lead compound, BMB-101.Financial details weren't disclosed.The study on Bright Minds' lead compound, BMB-101, utilized electroencephalogram, or EEG headsets from Firefly's partner, Zeto, and showed positive results through qEEG data analysis with recordings taken at multiple time points.Firefly Neuroscience said that the phase 1 trial is complete, and BMB-101 is now ready for phase 2.Shares of Firefly were up more than 22%, while Bright Minds retreated over 35% in recent Wednesday trading.Price: 3.84, Change: +0.71, Percent Change: +22.52","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}